Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic

Table 3 Effectiveness of pneumococcal conjugate vaccine schedule against VT-IPD

Outcome	Discordant pairs^a	Unadjusted (95% CI)	Adjusted (95% CI)^b
≥1 valid PCV dose compared to no doses
Overall	23/39	68.6% (14.5% to 89.2%)	67.2% (2.3% to 90.0%)
Born in Dominican Republic	23/39	70.6% (20.4% to 89.8%)	69.9% (11.9% to 90.6%)
Serotype 6A/6B ^c	7/12	93.3% (41.6% to 99.9%)	93.3% (13.0% to 99.9%)
Up-to-date with PCV compared to no doses ^d	17/39	71.7% (− 7.2% to 94.0%)	68.6% (− 29.6% to 93.9%)

^aMatched pairs with at least one discordant set (i.e. different vaccination status between case-patient and control). In conditional logistic regression, only discordant pairs contribute to the model
^bAdjusted for low weight-for-age Z score (i.e. malnutrition) and home built of wood (i.e. socioeconomic proxy)
^cOnly able to evaluate serotype 6A/6B because of lack of power to evaluate vaccine effectiveness for other individual serotypes
^dUp-to-date PCV13 was at least one dose for children aged ≤4 months and 13 days, at least two doses for children aged between 4 months plus 14 days and ≤ 12 months, and at least three doses for children > 12 months plus 14 days old at the time of hospital admission or reference day

ISSN: 1471-2334